We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.
Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.
As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.
WHO WE ARE
We deliver pharma products from Switzerland and from all over the world.
Our team in ELIXI International has a solid experience in the distribution of medical products.
History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.
FDA Approves SYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene
Vertex Pharmaceuticals Incorporated announced on Feb 12, 2018, that the U.S. Food and Drug Administration (FDA) approved SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) for treating the…
U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
On Feb. 7, 2018-- Gilead Sciences, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg,…
Hizentra (human normal immunoglobulin (SCIg)) – new indication Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) (inflammatory disease of the nerves)
On 25 January 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the…
FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
The U.S. Food and Drug Administration onFebruary 14, 2018, approved Erleada (apalutamide) for the treatment of patients with prostate cancer…
Elebrato Ellipta (fluticasone furoate / umeclidinium / vilanterol): new medicine authorised for the treatment of chronic obstructive pulmonary disease (COPD)
Elebrato Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). COPD…
Ocrevus is a medicine for treating multiple sclerosis – an inflammatory disease of the nervous system that causes symptoms such…
On January 26, 2018, the Food and Drug Administration approved lutetium Lu 177 dotatate (LUTATHERA, Advanced Accelerator Applications USA, Inc.)…
FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations
On January 12, 2018, the Food and Drug Administration granted approval to afatinib (Gilotrif, Boehringer Ingelheim Pharmaceutical, Inc.) for a…
FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer
On February 7, 2018, the Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga, Janssen Biotech Inc.) tablets in combination…
ELIXI International SA
Piazza Boffalora 4
6830 Chiasso / Switzerland
Tel: +41 91 682 20 40